POSEIDON, a phase 3 RCT, evaluated the effectiveness of tremelimumab plus durvalumab in 1013 patients with metastatic NSCLC without EGFR or ALK mutations regardless of histology. This evidence concerns the gene EGFR and non-small cell lung carcinoma.